GlassScriptPhysician profile
Lacey Wills
NPI 1275135212
$2,089.18
in general payments reported to CMS, 2019-2025
28 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $396 · 2023: $746 · 2024: $549 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $434.13 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $374.89 | 2022-2025 | |
| Glaxosmithkline, LLC. | $172.61 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $137.19 | 2022-2023 | |
| Lilly USA, LLC | $123.44 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $107.83 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $106.21 | 2022-2025 | Bevespi Aerosphere |
| Astellas Pharma US INC | $88.82 | 2022-2025 | Veozah |
| Boston Scientific Corporation | $47.54 | 2024-2025 | Watchman Flx |
| Exact Sciences Corporation | $44.11 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $43.59 | 2024-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $42.97 | 2023-2024 | Gardasil 9, Vaxelis, Rotateq |
| Amgen INC. | $41.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $37.83 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $34.34 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $33.25 | 2023 | Quviviq |
| Dexcom, INC. | $28.37 | 2025 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $20.74 | 2025 | Paragard T 380a |
| Almatica Pharma LLC | $20.41 | 2023 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $20.37 | 2023 | |
| Sanofi-Aventis U.S. LLC | $20.18 | 2024 | |
| Sobi, INC | $19.83 | 2022 | |
| Axsome Therapeutics, INC. | $15.74 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.41 | 2023 | Xifaxan |
| Cranial Technologies, INC | $15.15 | 2023 | Doc Band |
| Organon LLC | $14.51 | 2024 | |
| Shield Therapeutics INC | $14.39 | 2023 | Accrufer |
| Amneal Pharmaceuticals LLC | $13.94 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Wills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.